tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

SCYX Stock Latest News

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
Press ReleasesSCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
2M ago
SCYX
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
PremiumPress Releases
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
3M ago
SCYX
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
PremiumPress Releases
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
3M ago
SCYX
Scynexis price target lowered to $6 from $7 at Guggenheim
PremiumThe Fly
Scynexis price target lowered to $6 from $7 at Guggenheim
4M ago
SCYX
Scynexis reports FY23 EPS $1.39, consensus $1.42
PremiumThe Fly
Scynexis reports FY23 EPS $1.39, consensus $1.42
4M ago
SCYX
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
PremiumPress ReleasesSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
4M ago
SCYX
SCYX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
SCYX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
SCYX
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
PremiumPress Releases
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
6M ago
SCYX
Scynexis announces presentation of data from fungerp candidate SCY-247
PremiumThe Fly
Scynexis announces presentation of data from fungerp candidate SCY-247
6M ago
SCYX
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
PremiumPress Releases
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
6M ago
SCYX
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
PremiumPress Releases
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
7M ago
SCYX
Scynexis to present preclinical data on SCY-247
PremiumThe Fly
Scynexis to present preclinical data on SCY-247
7M ago
SCYX
Scynexis reports binding MOU with GSK for amendment to license agreement
PremiumThe FlyScynexis reports binding MOU with GSK for amendment to license agreement
7M ago
GSK
SCYX
Scynexis reports Q3 EPS (4c), consensus (15c)
PremiumThe Fly
Scynexis reports Q3 EPS (4c), consensus (15c)
8M ago
SCYX
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8M ago
SCYX
Scynexis files $200M mixed securities shelf
PremiumThe Fly
Scynexis files $200M mixed securities shelf
8M ago
SCYX
Scynexis files to sell 32.52M shares of common stock
PremiumThe Fly
Scynexis files to sell 32.52M shares of common stock
8M ago
SCYX
SCYX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
SCYX Earnings this Week: How Will it Perform?
9M ago
SCYX
Scynexis presents new preclinical data on SCY-247
PremiumThe Fly
Scynexis presents new preclinical data on SCY-247
9M ago
SCYX
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
PremiumPress ReleasesSCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
9M ago
SCYX
Scynexis issues voluntary nationwide recall of BREXAFEMME
PremiumThe Fly
Scynexis issues voluntary nationwide recall of BREXAFEMME
10M ago
SCYX
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
PremiumPress Releases
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
10M ago
SCYX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >